Beijing, China
BioGeometry
undisclosed funding
Series A
Summary
BioGeometry completed a Series A+ extension; the current extension proceeds were undisclosed. BioGeometry is AI models for drug and biomolecule design.
Investors
China Life Capital, Shanghai Biomedical Industry Fund, China Development Venture Capital, Reliance Investment, Guofang Venture Capital, Dacheng Wealth Capital